NCT04978025

Colloidal Silver, Treatment of COVID-19

Status unknown NA Last updated 27 July 2021

What this trial tests

NA trial testing Colloidal Silver in SARS (Severe Acute Respiratory Syndrome) in 50 participants. Status unknown.

Timeline

1 November 2020

Primary endpoint
1 November 2021

1 November 2021

Quick facts

Lead sponsor	Hôpital Universitaire Sahloul
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	50
Start date	1 November 2020
Primary completion	1 November 2021
Estimated completion	1 November 2021
Sites	1 location across Tunisia

Drugs / interventions tested

• Colloidal Silver — full drug profile →
• Placebo

Conditions studied

• SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →

Sponsor

Hôpital Universitaire Sahloul — full company profile →

Who can join

18 and older, any sex, with SARS (Severe Acute Respiratory Syndrome). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current Overview of Metal Nanoparticles' Synthesis, Characterization, and Biomedical Applications, with a Focus on Silver and Gold Nanoparticles.
   Burlec AF, Corciova A, Boev M, Batir-Marin D, et al · · 2023 · cited 93× · PMID 37895881 · DOI 10.3390/ph16101410
2. Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation.
   Zheng Y, Luo S, Xu M, He Q, et al · · 2024 · cited 47× · PMID 39309496 · DOI 10.1016/j.apsb.2024.06.015
3. Biomedical Applications of Plant Extract-Synthesized Silver Nanoparticles.
   Simon S, Sibuyi NRS, Fadaka AO, Meyer S, et al · · 2022 · cited 46× · PMID 36359308 · DOI 10.3390/biomedicines10112792
4. Plant Extract-Synthesized Silver Nanoparticles for Application in Dental Therapy.
   Ahmed O, Sibuyi NRS, Fadaka AO, Madiehe MA, et al · · 2022 · cited 41× · PMID 35214112 · DOI 10.3390/pharmaceutics14020380
5. Aerosol pulmonary immune engineering.
   Sudduth ER, Trautmann-Rodriguez M, Gill N, Bomb K, et al · · 2023 · cited 18× · PMID 37100206 · DOI 10.1016/j.addr.2023.114831
6. Clinical translation and landscape of silver nanoparticles.
   Dias M, Zhang R, Lammers T, Pallares RM. · · 2025 · cited 17× · PMID 39377875 · DOI 10.1007/s13346-024-01716-5
7. Treatment of lung diseases <i>via</i> nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?
   George M, Boukherroub R, Sanyal A, Szunerits S. · · 2025 · cited 7× · PMID 40124344 · DOI 10.1016/j.mtbio.2025.101616
8. Silver Nanoparticle-Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review.
   Mosidze E, Franci G, Dell'Annunziata F, Capuano N, et al · · 2025 · cited 4× · PMID 40352632 · DOI 10.1002/gch2.202400380